Dr. Xia’s research interests involve target identification, characterization, validation and early stage drug development, with exploration of clinical biomarkers for AD. He has established multiple platforms to quantify pathological proteins like amyloid ß protein (Aß), Tau, neuroinflammatory factors, and related biomarkers. He also develops Mass Spectrometry-based analytic approaches to explore biomarkers for AD and other central nervous system disorders.